For the quarter ended March 2024, Amicus Therapeutics (FOLD) reported income of $110.4 million, up 28% over the identical interval final 12 months. EPS got here in at -$0.02, in comparison with -$0.18 within the year-ago quarter.
The reported income compares to the Zacks Consensus Estimate of $111.62 million, representing a shock of -1.09%. The corporate delivered an EPS shock of +66.67%, with the consensus EPS estimate being -$0.06.
Whereas buyers intently watch year-over-year modifications in headline numbers — income and earnings — and the way they evaluate to Wall Avenue expectations to find out their subsequent plan of action, some key metrics all the time present a greater perception into an organization’s underlying efficiency.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps buyers mission a inventory’s value efficiency extra precisely.
Right here is how Amicus Therapeutics carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Avenue analysts:
- Geographic revenues- Ex-U.S: $73.03 million in comparison with the $72.73 million common estimate primarily based on two analysts. The reported quantity represents a change of +27.1% 12 months over 12 months.
- Geographic revenues- United States: $37.38 million versus the two-analyst common estimate of $39.16 million. The reported quantity represents a year-over-year change of +29.6%.
- Web Product Revenues- Pombiliti + Opfolda: $11.04 million versus $12.49 million estimated by 5 analysts on common.
- Web Product Revenues- Galafold: $99.36 million versus $99.13 million estimated by 5 analysts on common.
View all Key Company Metrics for Amicus Therapeutics here>>>
Shares of Amicus Therapeutics have returned -10% over the previous month versus the Zacks S&P 500 composite’s -0.3% change. The inventory at present has a Zacks Rank #4 (Promote), indicating that it might underperform the broader market within the close to time period.
Zacks Names “Single Finest Decide to Double”
From 1000’s of shares, 5 Zacks consultants every have chosen their favourite to skyrocket +100% or extra in months to come back. From these 5, Director of Analysis Sheraz Mian hand-picks one to have probably the most explosive upside of all.
It’s an American AI firm that’s using low proper now, but it surely has rounded up purchasers like BMW, GE, Dell Pc, and Bosch. It has prospects for not simply doubling however quadrupling within the 12 months to come back. After all, all our picks aren’t winners however this one might far surpass earlier Zacks’ Shares Set to Double like Boston Beer Firm which shot up +143.0% in little greater than 9 months and NVIDIA which boomed +175.9% in a single 12 months.
Free: See Our Top Stock And 4 Runners Up
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
